Reviews Zyban


No reviews yet.

Zyban Drug Description
ZYBAN®
(bupropion hydrochloride) Sustained-Release Tablets

WARNING
Serious neuropsychiatric events, including but not limited
to depression, suicidal ideation, suicide attempt, and completed suicide have
been reported in patients taking ZYBAN for smoking cessation. Some cases may
have been complicated by the symptoms of nicotine withdrawal in patients who
stopped smoking. Depressed mood may be a symptom of nicotine withdrawal.
Depression, rarely including suicidal ideation, has been reported in smokers undergoing
a smoking cessation attempt without medication. However, some of these symptoms
have occurred in patients taking ZYBAN who continued to smoke.
All patients being treated with ZYBAN should be observed for
neuropsychiatric symptoms including changes in behavior, hostility, agitation,
depressed mood, and suicide-related events, including ideation, behavior, and
attempted suicide. These symptoms, as well as worsening of preexisting
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the post-marketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have
occurred in patients with and without pre-existing psychiatric disease; some
have experienced worsening of their psychiatric illnesses. Patients with
serious psychiatric illness such as schizophrenia, bipolar disorder, and major
depressive disorder did not participate in the pre-marketing studies of ZYBAN.
Advise patients and caregivers that the patient should
stop taking ZYBAN and contact a healthcare provider immediately if agitation,
hostility, depressed mood, or changes in thinking or behavior that are not
typical for the patient are observed, or if the patient develops suicidal
ideation or suicidal behavior. In many post-marketing cases, resolution of
symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care
should be provided until symptoms resolve.
The risks of ZYBAN should be weighed against the benefits of its use. ZYBAN
has been demonstrated to increase the likelihood of abstinence from smoking
for as long as 6 months compared to treatment with placebo. The health benefits
of quitting smoking are immediate and substantial. (See WARNINGS:
Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation Treatment
and PRECAUTIONS: Information for Patients.)
Use in Treating Psychiatric Disorders: Although ZYBAN is not indicated
for treatment of depression, it contains the same active ingredient as the
antidepressant medications WELLBUTRIN®, WELLBUTRIN SR®, and WELLBUTRIN
XL®. Antidepressants increased the risk compared to placebo of suicidal
thinking and behavior (suicidality) in children, adolescents, and young adults
in short-term studies of major depressive disorder (MDD) and other psychiatric
disorders. Anyone considering the use of ZYBAN or any other antidepressant
in a child, adolescent, or young adult must balance this risk with the clinical
need. Short-term studies did not show an increase in the risk of suicidality
with antidepressants compared to placebo in adults beyond age 24; there was
a reduction in risk with antidepressants compared to placebo in adults aged
65 and older. Depression and certain other psychiatric disorders are themselves
associated with increases in the risk of suicide. Patients of all ages who
are started on antidepressant therapy should be monitored appropriately and
observed closely for clinical worsening, suicidality, or unusual changes in
behavior. Families and caregivers should be advised of the need for close
observation and communication with the prescriber. ZYBAN is not approved for
use in pediatric patients. (See WARNINGS: Clinical
Worsening and Suicide Risk in Treating Psychiatric Disorders, PRECAUTIONS:
Information for Patients, and PRECAUTIONS:
Pediatric Use.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Zyban »




ZYBAN (bupropion hydrochloride) Sustained-Release Tablets
are a non-nicotine aid to smoking cessation. ZYBAN is chemically unrelated to
nicotine or other agents currently used in the treatment of nicotine addiction.
Initially developed and marketed as an antidepressant (WELLBUTRIN [bupropion
hydrochloride] Tablets and WELLBUTRIN SR [bupropion hydrochloride]
Sustained-Release Tablets), ZYBAN is also chemically unrelated to tricyclic,
tetracyclic, selective serotonin re-uptake inhibitor, or other known
antidepressant agents. Its structure closely resembles that of diethylpropion;
it is related to phenylethylamines. It is
(±)-1-(3chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride.
The molecular weight is 276.2. The molecular formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia on
the oral mucosa. The structural formula is:








ZYBAN Tablets are supplied for oral administration as 150-mg
(purple), film-coated, sustained-release tablets. Each tablet contains the
labeled amount of bupropion hydrochloride and the inactive ingredients carnauba
wax, cysteine hydrochloride, hypromellose, magnesium stearate, microcrystalline
cellulose, polyethylene glycol, polysorbate 80 and titanium dioxide and is
printed with edible black ink. In addition, the 150-mg tablet contains FD&C
Blue No. 2 Lake and FD&C Red No. 40 Lake.Last reviewed on RxList: 7/24/2009




Zyban Drug Description
ZYBAN®
(bupropion hydrochloride) Sustained-Release Tablets

WARNING
Serious neuropsychiatric events, including but not limited
to depression, suicidal ideation, suicide attempt, and completed suicide have
been reported in patients taking ZYBAN for smoking cessation. Some cases may
have been complicated by the symptoms of nicotine withdrawal in patients who
stopped smoking. Depressed mood may be a symptom of nicotine withdrawal.
Depression, rarely including suicidal ideation, has been reported in smokers undergoing
a smoking cessation attempt without medication. However, some of these symptoms
have occurred in patients taking ZYBAN who continued to smoke.
All patients being treated with ZYBAN should be observed for
neuropsychiatric symptoms including changes in behavior, hostility, agitation,
depressed mood, and suicide-related events, including ideation, behavior, and
attempted suicide. These symptoms, as well as worsening of preexisting
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the post-marketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have
occurred in patients with and without pre-existing psychiatric disease; some
have experienced worsening of their psychiatric illnesses. Patients with
serious psychiatric illness such as schizophrenia, bipolar disorder, and major
depressive disorder did not participate in the pre-marketing studies of ZYBAN.
Advise patients and caregivers that the patient should
stop taking ZYBAN and contact a healthcare provider immediately if agitation,
hostility, depressed mood, or changes in thinking or behavior that are not
typical for the patient are observed, or if the patient develops suicidal
ideation or suicidal behavior. In many post-marketing cases, resolution of
symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care
should be provided until symptoms resolve.
The risks of ZYBAN should be weighed against the benefits of its use. ZYBAN
has been demonstrated to increase the likelihood of abstinence from smoking
for as long as 6 months compared to treatment with placebo. The health benefits
of quitting smoking are immediate and substantial. (See WARNINGS:
Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation Treatment
and PRECAUTIONS: Information for Patients.)
Use in Treating Psychiatric Disorders: Although ZYBAN is not indicated
for treatment of depression, it contains the same active ingredient as the
antidepressant medications WELLBUTRIN®, WELLBUTRIN SR®, and WELLBUTRIN
XL®. Antidepressants increased the risk compared to placebo of suicidal
thinking and behavior (suicidality) in children, adolescents, and young adults
in short-term studies of major depressive disorder (MDD) and other psychiatric
disorders. Anyone considering the use of ZYBAN or any other antidepressant
in a child, adolescent, or young adult must balance this risk with the clinical
need. Short-term studies did not show an increase in the risk of suicidality
with antidepressants compared to placebo in adults beyond age 24; there was
a reduction in risk with antidepressants compared to placebo in adults aged
65 and older. Depression and certain other psychiatric disorders are themselves
associated with increases in the risk of suicide. Patients of all ages who
are started on antidepressant therapy should be monitored appropriately and
observed closely for clinical worsening, suicidality, or unusual changes in
behavior. Families and caregivers should be advised of the need for close
observation and communication with the prescriber. ZYBAN is not approved for
use in pediatric patients. (See WARNINGS: Clinical
Worsening and Suicide Risk in Treating Psychiatric Disorders, PRECAUTIONS:
Information for Patients, and PRECAUTIONS:
Pediatric Use.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Zyban »




ZYBAN (bupropion hydrochloride) Sustained-Release Tablets
are a non-nicotine aid to smoking cessation. ZYBAN is chemically unrelated to
nicotine or other agents currently used in the treatment of nicotine addiction.
Initially developed and marketed as an antidepressant (WELLBUTRIN [bupropion
hydrochloride] Tablets and WELLBUTRIN SR [bupropion hydrochloride]
Sustained-Release Tablets), ZYBAN is also chemically unrelated to tricyclic,
tetracyclic, selective serotonin re-uptake inhibitor, or other known
antidepressant agents. Its structure closely resembles that of diethylpropion;
it is related to phenylethylamines. It is
(±)-1-(3chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride.
The molecular weight is 276.2. The molecular formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia on
the oral mucosa. The structural formula is:








ZYBAN Tablets are supplied for oral administration as 150-mg
(purple), film-coated, sustained-release tablets. Each tablet contains the
labeled amount of bupropion hydrochloride and the inactive ingredients carnauba
wax, cysteine hydrochloride, hypromellose, magnesium stearate, microcrystalline
cellulose, polyethylene glycol, polysorbate 80 and titanium dioxide and is
printed with edible black ink. In addition, the 150-mg tablet contains FD&C
Blue No. 2 Lake and FD&C Red No. 40 Lake.Last reviewed on RxList: 7/24/2009




Zyban Drug Description
ZYBAN®
(bupropion hydrochloride) Sustained-Release Tablets

WARNING
Serious neuropsychiatric events, including but not limited
to depression, suicidal ideation, suicide attempt, and completed suicide have
been reported in patients taking ZYBAN for smoking cessation. Some cases may
have been complicated by the symptoms of nicotine withdrawal in patients who
stopped smoking. Depressed mood may be a symptom of nicotine withdrawal.
Depression, rarely including suicidal ideation, has been reported in smokers undergoing
a smoking cessation attempt without medication. However, some of these symptoms
have occurred in patients taking ZYBAN who continued to smoke.
All patients being treated with ZYBAN should be observed for
neuropsychiatric symptoms including changes in behavior, hostility, agitation,
depressed mood, and suicide-related events, including ideation, behavior, and
attempted suicide. These symptoms, as well as worsening of preexisting
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the post-marketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have
occurred in patients with and without pre-existing psychiatric disease; some
have experienced worsening of their psychiatric illnesses. Patients with
serious psychiatric illness such as schizophrenia, bipolar disorder, and major
depressive disorder did not participate in the pre-marketing studies of ZYBAN.
Advise patients and caregivers that the patient should
stop taking ZYBAN and contact a healthcare provider immediately if agitation,
hostility, depressed mood, or changes in thinking or behavior that are not
typical for the patient are observed, or if the patient develops suicidal
ideation or suicidal behavior. In many post-marketing cases, resolution of
symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care
should be provided until symptoms resolve.
The risks of ZYBAN should be weighed against the benefits of its use. ZYBAN
has been demonstrated to increase the likelihood of abstinence from smoking
for as long as 6 months compared to treatment with placebo. The health benefits
of quitting smoking are immediate and substantial. (See WARNINGS:
Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation Treatment
and PRECAUTIONS: Information for Patients.)
Use in Treating Psychiatric Disorders: Although ZYBAN is not indicated
for treatment of depression, it contains the same active ingredient as the
antidepressant medications WELLBUTRIN®, WELLBUTRIN SR®, and WELLBUTRIN
XL®. Antidepressants increased the risk compared to placebo of suicidal
thinking and behavior (suicidality) in children, adolescents, and young adults
in short-term studies of major depressive disorder (MDD) and other psychiatric
disorders. Anyone considering the use of ZYBAN or any other antidepressant
in a child, adolescent, or young adult must balance this risk with the clinical
need. Short-term studies did not show an increase in the risk of suicidality
with antidepressants compared to placebo in adults beyond age 24; there was
a reduction in risk with antidepressants compared to placebo in adults aged
65 and older. Depression and certain other psychiatric disorders are themselves
associated with increases in the risk of suicide. Patients of all ages who
are started on antidepressant therapy should be monitored appropriately and
observed closely for clinical worsening, suicidality, or unusual changes in
behavior. Families and caregivers should be advised of the need for close
observation and communication with the prescriber. ZYBAN is not approved for
use in pediatric patients. (See WARNINGS: Clinical
Worsening and Suicide Risk in Treating Psychiatric Disorders, PRECAUTIONS:
Information for Patients, and PRECAUTIONS:
Pediatric Use.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Zyban »




ZYBAN (bupropion hydrochloride) Sustained-Release Tablets
are a non-nicotine aid to smoking cessation. ZYBAN is chemically unrelated to
nicotine or other agents currently used in the treatment of nicotine addiction.
Initially developed and marketed as an antidepressant (WELLBUTRIN [bupropion
hydrochloride] Tablets and WELLBUTRIN SR [bupropion hydrochloride]
Sustained-Release Tablets), ZYBAN is also chemically unrelated to tricyclic,
tetracyclic, selective serotonin re-uptake inhibitor, or other known
antidepressant agents. Its structure closely resembles that of diethylpropion;
it is related to phenylethylamines. It is
(±)-1-(3chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride.
The molecular weight is 276.2. The molecular formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia on
the oral mucosa. The structural formula is:








ZYBAN Tablets are supplied for oral administration as 150-mg
(purple), film-coated, sustained-release tablets. Each tablet contains the
labeled amount of bupropion hydrochloride and the inactive ingredients carnauba
wax, cysteine hydrochloride, hypromellose, magnesium stearate, microcrystalline
cellulose, polyethylene glycol, polysorbate 80 and titanium dioxide and is
printed with edible black ink. In addition, the 150-mg tablet contains FD&C
Blue No. 2 Lake and FD&C Red No. 40 Lake.Last reviewed on RxList: 7/24/2009




Zyban Drug Description
ZYBAN®
(bupropion hydrochloride) Sustained-Release Tablets

WARNING
Serious neuropsychiatric events, including but not limited
to depression, suicidal ideation, suicide attempt, and completed suicide have
been reported in patients taking ZYBAN for smoking cessation. Some cases may
have been complicated by the symptoms of nicotine withdrawal in patients who
stopped smoking. Depressed mood may be a symptom of nicotine withdrawal.
Depression, rarely including suicidal ideation, has been reported in smokers undergoing
a smoking cessation attempt without medication. However, some of these symptoms
have occurred in patients taking ZYBAN who continued to smoke.
All patients being treated with ZYBAN should be observed for
neuropsychiatric symptoms including changes in behavior, hostility, agitation,
depressed mood, and suicide-related events, including ideation, behavior, and
attempted suicide. These symptoms, as well as worsening of preexisting
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the post-marketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have
occurred in patients with and without pre-existing psychiatric disease; some
have experienced worsening of their psychiatric illnesses. Patients with
serious psychiatric illness such as schizophrenia, bipolar disorder, and major
depressive disorder did not participate in the pre-marketing studies of ZYBAN.
Advise patients and caregivers that the patient should
stop taking ZYBAN and contact a healthcare provider immediately if agitation,
hostility, depressed mood, or changes in thinking or behavior that are not
typical for the patient are observed, or if the patient develops suicidal
ideation or suicidal behavior. In many post-marketing cases, resolution of
symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care
should be provided until symptoms resolve.
The risks of ZYBAN should be weighed against the benefits of its use. ZYBAN
has been demonstrated to increase the likelihood of abstinence from smoking
for as long as 6 months compared to treatment with placebo. The health benefits
of quitting smoking are immediate and substantial. (See WARNINGS:
Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation Treatment
and PRECAUTIONS: Information for Patients.)
Use in Treating Psychiatric Disorders: Although ZYBAN is not indicated
for treatment of depression, it contains the same active ingredient as the
antidepressant medications WELLBUTRIN®, WELLBUTRIN SR®, and WELLBUTRIN
XL®. Antidepressants increased the risk compared to placebo of suicidal
thinking and behavior (suicidality) in children, adolescents, and young adults
in short-term studies of major depressive disorder (MDD) and other psychiatric
disorders. Anyone considering the use of ZYBAN or any other antidepressant
in a child, adolescent, or young adult must balance this risk with the clinical
need. Short-term studies did not show an increase in the risk of suicidality
with antidepressants compared to placebo in adults beyond age 24; there was
a reduction in risk with antidepressants compared to placebo in adults aged
65 and older. Depression and certain other psychiatric disorders are themselves
associated with increases in the risk of suicide. Patients of all ages who
are started on antidepressant therapy should be monitored appropriately and
observed closely for clinical worsening, suicidality, or unusual changes in
behavior. Families and caregivers should be advised of the need for close
observation and communication with the prescriber. ZYBAN is not approved for
use in pediatric patients. (See WARNINGS: Clinical
Worsening and Suicide Risk in Treating Psychiatric Disorders, PRECAUTIONS:
Information for Patients, and PRECAUTIONS:
Pediatric Use.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Zyban »




ZYBAN (bupropion hydrochloride) Sustained-Release Tablets
are a non-nicotine aid to smoking cessation. ZYBAN is chemically unrelated to
nicotine or other agents currently used in the treatment of nicotine addiction.
Initially developed and marketed as an antidepressant (WELLBUTRIN [bupropion
hydrochloride] Tablets and WELLBUTRIN SR [bupropion hydrochloride]
Sustained-Release Tablets), ZYBAN is also chemically unrelated to tricyclic,
tetracyclic, selective serotonin re-uptake inhibitor, or other known
antidepressant agents. Its structure closely resembles that of diethylpropion;
it is related to phenylethylamines. It is
(±)-1-(3chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride.
The molecular weight is 276.2. The molecular formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia on
the oral mucosa. The structural formula is:








ZYBAN Tablets are supplied for oral administration as 150-mg
(purple), film-coated, sustained-release tablets. Each tablet contains the
labeled amount of bupropion hydrochloride and the inactive ingredients carnauba
wax, cysteine hydrochloride, hypromellose, magnesium stearate, microcrystalline
cellulose, polyethylene glycol, polysorbate 80 and titanium dioxide and is
printed with edible black ink. In addition, the 150-mg tablet contains FD&C
Blue No. 2 Lake and FD&C Red No. 40 Lake.Last reviewed on RxList: 7/24/2009




Zyban Drug Description
ZYBAN®
(bupropion hydrochloride) Sustained-Release Tablets

WARNING
Serious neuropsychiatric events, including but not limited
to depression, suicidal ideation, suicide attempt, and completed suicide have
been reported in patients taking ZYBAN for smoking cessation. Some cases may
have been complicated by the symptoms of nicotine withdrawal in patients who
stopped smoking. Depressed mood may be a symptom of nicotine withdrawal.
Depression, rarely including suicidal ideation, has been reported in smokers undergoing
a smoking cessation attempt without medication. However, some of these symptoms
have occurred in patients taking ZYBAN who continued to smoke.
All patients being treated with ZYBAN should be observed for
neuropsychiatric symptoms including changes in behavior, hostility, agitation,
depressed mood, and suicide-related events, including ideation, behavior, and
attempted suicide. These symptoms, as well as worsening of preexisting
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the post-marketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have
occurred in patients with and without pre-existing psychiatric disease; some
have experienced worsening of their psychiatric illnesses. Patients with
serious psychiatric illness such as schizophrenia, bipolar disorder, and major
depressive disorder did not participate in the pre-marketing studies of ZYBAN.
Advise patients and caregivers that the patient should
stop taking ZYBAN and contact a healthcare provider immediately if agitation,
hostility, depressed mood, or changes in thinking or behavior that are not
typical for the patient are observed, or if the patient develops suicidal
ideation or suicidal behavior. In many post-marketing cases, resolution of
symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care
should be provided until symptoms resolve.
The risks of ZYBAN should be weighed against the benefits of its use. ZYBAN
has been demonstrated to increase the likelihood of abstinence from smoking
for as long as 6 months compared to treatment with placebo. The health benefits
of quitting smoking are immediate and substantial. (See WARNINGS:
Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation Treatment
and PRECAUTIONS: Information for Patients.)
Use in Treating Psychiatric Disorders: Although ZYBAN is not indicated
for treatment of depression, it contains the same active ingredient as the
antidepressant medications WELLBUTRIN®, WELLBUTRIN SR®, and WELLBUTRIN
XL®. Antidepressants increased the risk compared to placebo of suicidal
thinking and behavior (suicidality) in children, adolescents, and young adults
in short-term studies of major depressive disorder (MDD) and other psychiatric
disorders. Anyone considering the use of ZYBAN or any other antidepressant
in a child, adolescent, or young adult must balance this risk with the clinical
need. Short-term studies did not show an increase in the risk of suicidality
with antidepressants compared to placebo in adults beyond age 24; there was
a reduction in risk with antidepressants compared to placebo in adults aged
65 and older. Depression and certain other psychiatric disorders are themselves
associated with increases in the risk of suicide. Patients of all ages who
are started on antidepressant therapy should be monitored appropriately and
observed closely for clinical worsening, suicidality, or unusual changes in
behavior. Families and caregivers should be advised of the need for close
observation and communication with the prescriber. ZYBAN is not approved for
use in pediatric patients. (See WARNINGS: Clinical
Worsening and Suicide Risk in Treating Psychiatric Disorders, PRECAUTIONS:
Information for Patients, and PRECAUTIONS:
Pediatric Use.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Zyban »




ZYBAN (bupropion hydrochloride) Sustained-Release Tablets
are a non-nicotine aid to smoking cessation. ZYBAN is chemically unrelated to
nicotine or other agents currently used in the treatment of nicotine addiction.
Initially developed and marketed as an antidepressant (WELLBUTRIN [bupropion
hydrochloride] Tablets and WELLBUTRIN SR [bupropion hydrochloride]
Sustained-Release Tablets), ZYBAN is also chemically unrelated to tricyclic,
tetracyclic, selective serotonin re-uptake inhibitor, or other known
antidepressant agents. Its structure closely resembles that of diethylpropion;
it is related to phenylethylamines. It is
(±)-1-(3chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride.
The molecular weight is 276.2. The molecular formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia on
the oral mucosa. The structural formula is:








ZYBAN Tablets are supplied for oral administration as 150-mg
(purple), film-coated, sustained-release tablets. Each tablet contains the
labeled amount of bupropion hydrochloride and the inactive ingredients carnauba
wax, cysteine hydrochloride, hypromellose, magnesium stearate, microcrystalline
cellulose, polyethylene glycol, polysorbate 80 and titanium dioxide and is
printed with edible black ink. In addition, the 150-mg tablet contains FD&C
Blue No. 2 Lake and FD&C Red No. 40 Lake.Last reviewed on RxList: 7/24/2009





Other reviews about Zyban on wordpress

Is Zyban a Girly way to Quit Nicotine?
  by smokeless
Reading various stuff around the net on giving up nicotine I get the impression that taking Zyban, a nicotine free drug that lessens the cravings and generally helps […]


How to Quit Smoking with Zyban
  by brahimbb17
If you are a smoker who has tried to quit multiples times and been unsuccessful, do not give up. There is hope and it is called Zyban. Zyban […]


Zyban Quit Smoking Now
  by sideeffectsofzyban
There has been a gigantic push over the past few years to get people to quit smoking. Some states in the US have enacted legislation that prohibits smoking […]


FDA MedWatch - Varenicline (Chantix) and Bupropion (Zyban, Wellbutrin, and generics)
  by irbtipoftheweek
FDA notified healthcare professionals and patients that it has required the manufacturers of the smoking cessation aids varenicline (Chantix) and bupropion (Zyban and generics) to add new Boxed […]


FDA: Chantix and Zyban anti-smoking drugs need warning
  by Drug Recall Watch
U.S. health officials said on Wednesday they ordered Pfizer Inc and GlaxoSmithKline PLC to add strong "black box" warnings on smoking cessation drugs to highlight a risk of […]


Chantix and Zyban (Wellbutrin) to get black box warnings
  by giannakali
More black box warnings for an antidepressant (Wellbutrin) that doubles as a quit smoking drug (so it's also called Zyban) and Chantix the quit smoking drug with a […]


Quit smoking successfully within a short time by using Zyban Generic
  by uschemist
Smoking is not an uncontrolled habit. Zyban Generic Medicine you can give up the unhealthy smoking habit very easily and within the short period. Within a time of […]


Zyban Quit Smoking
  by bizguru
We all know how addictive smoking can be, because either we have our own personal experience battling the habit or someone close to us doing that. For those […]


Zyban Quit Smoking Method
  by smokingsideeffects
Zyban is prescribed as an antidepressant and a quit smoking therapy. It was the […]


Zyban Quit Smoking Method
  by jingxiwang1122
by sweethell Zyban Quit Smoking Method Zyban is prescribed as an antidepressant and a quit […]



Other reviews about Zyban on web:

Quit Smoking With the E-Z Quit Artificial Cigarette. Proudly Serving The Internet Since June, 1997 Zyban Quit Smoking Drug


Bupropion (also known as Wellbutrin, Zyban, Voxra, Budeprion, or Aplenzin; formerly known as amfebutamone) is an atypical antidepressant and smoking cessation aid. Bupropion - Wikipedia, the free encyclopedia


Accurate, FDA approved Zyban information for healthcare professionals and patients - brought to you by Drugs.com. Zyban Official FDA information, side effects and uses.


Learn about the prescription medication Zyban (Bupropion Hcl), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Zyban (Bupropion Hcl) Drug Information: Uses, Side Effects, Drug ...


Zyban (bupropion) helps people stop smoking by reducing cravings and other withdrawal effects. Includes Zyban side effects, interactions and indications. Zyban Information from Drugs.com


Prescribing information for US residents. ZYBAN® (bupropion hydrochloride) Sustained-Release Tablets


Welcome page to the US site for GSK; includes banner, callouts, quick links to areas deeper in the site, and featured material teasers United States Homepage - GlaxoSmithKline


Zyban is a popular prescription medication commonly used to help people quit smoking. Learn the side effects of Zyban, how effective it is, and how to get Zyban. Zyban - Side Effects - Quitting Smoking with Zyban - How to Get Zyban


Zyban is an antidepressant used for helping certain patients to stop smoking cigarettes. Side effects and interactions are available at drugstore.com; plus get home delivery from a ... Zyban - drugstore.com. Low prices, side effects, interactions.


Zyban is bupropion hydrochloride, a medication that targets addicting substances in the human brain, brought by smoking nicotine. These are dopamine and norepinephrine, which Zyban - Kosmix : Reference, Videos, Images, News, Shopping and ...





Featured Reviews

Reviews IDM Club Bucharest

Since the january 2010 I am going to IDM CLub on a regulary bases, to the semiolimpic pool, to swim. By far is the best pool in Bucharest: - very very clean - water has 31 degrees celsius - great lockers - VERY FEW PEOPLE to bump into -...
Read More  |  Review This
Reviews Inderide

Inderide Drug Description INDERIDE® (propranolol hydrochloride [Inderal®] and hydrochlorothiazide) DRUG DESCRIPTION What are the possible side effects of hydrochlorothiazide and propranolol (Inderide)? Get emergency medical...
Read More  |  Review This
Reviews Atovaquone

Mepron Drug Description MEPRON® (atovaquone) Suspension DRUG DESCRIPTION What are the possible side effects of atovaquone (Mepron)? Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty...
Read More  |  Review This
Reviews Dimercarprol Injection

Bal in Oil Ampules Drug Description BAL in Oil Ampules (dimercarprol injection, USP) DRUG DESCRIPTION What are the possible side effects of dimercaprol (BAL In Oil)? Get emergency medical help if you have any of these signs of...
Read More  |  Review This
Reviews Digoxin Immune Fab

Digibind Drug Description DIGIBIND® Digoxin Immune Fab (Ovine) DRUG DESCRIPTION What are the possible side effects of digoxin immune FAB (Digibind, DigiFab)? Get emergency medical help if you have any of these signs of an allergic...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....